SPIRE - new trial to test drug for resistant bladder cancer is launched

“Studying drug resistance in cancer helps us get one step ahead of the disease, allowing us to target its defences. We’ve seen a lot of drug combinations in the news recently and we hope that this approach will help in bladder cancer where there are few options for patients.” - Nigel Blackburn, Cancer Research UK’s director of drug development

SPIRE is a clinical trial to test a drug which may stop bladder cancers becoming resistant to chemotherapy is being launched by the Southampton Clinical Trials Unit and the Experimental Cancer Medicines Centre (ECMC) network

Find out more information at the following links:

http://www.fiercebiotech.com/biotech/cruk-pairs-astex-dnmt-inhibitor-chemo-for-bladder-cancer-combo-trial

http://www.pharmatimes.com/news/cr_uk_launches_bladder_cancer_drug_trial_1100567?utm_source=PT+Daily+Newsletter&utm_medium=email&utm_campaign=pt+daily+news+alert

http://ecancer.org/news/9997-cancer-research-uk-launches-new-trial-to-test-drug-against-resistant-bladder-cancer.php

http://www.charitytoday.co.uk/new-trial-to-test-drug-against-resistant-bladder-cancer/

http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-08-15-cancer-research-uk-launches-new-trial-to-test-drug-against-resistant-bladder-cancer